McKesson stock commits USD 1.4 billion to Option Care Health

Published on 10/06/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock was trading at USD 918.62 on October 6, 2026 as the company entered a USD 5.8 billion Option Care Health deal. Q1 revenue rose 7.7 percent.

Schwarzweißfoto eines Lagerarbeiters mit Wagen voller Kartons in großer Lagerhalle — Schwarzweiß-Reportagefoto dokumentiert McKesson Corporation ISIN US58155Q1031 im täglichen Logistikbetrieb mit Arbeiter im Pharma-Vertriebslager, Illustration mit AI erstellt.

McKesson stock (ISIN US58155Q1031) was trading at USD 918.62 on the NYSE on October 6, 2026 at 11:14 a.m. ET, as the healthcare distributor announced a USD 1.4 billion investment in Option Care Health. The transaction gives McKesson a 49 percent minority stake in the infusion services provider and places the company deeper into community-based specialty care.

Option Care deal adds specialty exposure

As Reuters reported on October 6, 2026, McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for an enterprise value of USD 5.8 billion. The offer price of USD 32.05 per Option Care share represents a 37.1 percent premium to its October 5 closing price.

According to StockTitan in the October 6, 2026 filing, CD&R will hold approximately 51 percent while McKesson will hold approximately 49 percent. The deal is expected to close in the first half of calendar year 2027, subject to stockholder and regulatory approvals.

Q1 growth supports the strategy

McKesson's latest reported quarter ended June 30, 2026. Revenue reached USD 105.38 billion, up 7.7 percent from the prior-year quarter, while adjusted earnings per share rose 20 percent to USD 9.93, according to MarketBeat. The same quarter also showed a contrast in reporting measures, with GAAP diluted earnings per share at USD 5.15.

McKesson reaffirmed fiscal 2027 adjusted earnings per share guidance of USD 44.20 to USD 45.00 in its October 1, 2026 release, while the Option Care transaction adds a new capital commitment before the next results update. The investment therefore links McKesson's distribution scale with a specialty-care platform rather than representing a change to its core pharmaceutical business.

Analysts see room above the price

MarketBeat reported on October 5, 2026 that 18 analysts covered McKesson, with a Moderate Buy consensus and an average price target of USD 973.44. The target stands 6.0 percent above the USD 918.62 price, while the 52-week range extends from USD 723.68 to USD 999.00.

McKesson stock trades below yearly high

McKesson stock was last at USD 918.62 on the NYSE on October 6, 2026 at 11:14 a.m. ET, up USD 3.17, or 0.35 percent, from the prior close. Market capitalization stood at USD 107.6 billion and volume was 128,275 shares.